Cover Image

FLT3‐ITD regulation of the endoplasmic reticulum functions in acute myeloid leukemia

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	María Turos‐Cabal, Ana M. Sánchez‐Sánchez, Noelia Puente‐Moncada, Federico Herrera, Isaac Antolin, Carmen Rodríguez, Vanesa Martín
Format:	Artículo Open Access
Published:	Wiley 2024
Subjects:	Hematological Oncology
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Secondary acute myeloid leukemia and early infection are independent predictors of poor survival in acute myeloid leukemia treated with hypomethylating agents and venetoclax
by: Stefano Cordella, et al.
Published: (2024)

Isocitrate dehydrogenase 2 mutation promotes cytarabine resistance in acute myeloid leukemia by Warburg effect
by: Jinrong Yang, et al.
Published: (2024)

Research on the mechanism of HOPX‐HDAC2 interaction inducing differentiation blockage in acute myeloid leukemia
by: Fang He, et al.
Published: (2024)

A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia
by: Sudhir Manda, et al.
Published: (2024)

Usefulness of KIT mutant transcript levels for monitoring measurable residual disease in t (8;21) acute myeloid leukemia
by: Yuan Sun, et al.
Published: (2024)

Venetoclax plus daunorubicin and cytarabine in newly diagnosed acute myeloid leukemia patients: A propensity score‐matched analysis
by: Rong Wang, et al.
Published: (2024)

Characteristics, outcomes and health care utilization of patients with acute myeloid leukemia aged 70 years or older: A single‐center retrospective analysis
by: Marie Anne‐Catherine Neumann, et al.
Published: (2024)

Clinical characteristics and prognosis of acute myeloid leukemia patients with Runt‐related transcription factor 1 mutation: A single‐center retrospective analysis
by: Lin‐Ya Wang, et al.
Published: (2024)

Direct determination of chronic myeloid leukemia prevalence in Lombardy—Italy: Global implications
by: N. Polverelli, et al.
Published: (2024)

Treatment‐free remission as a new goal in the management of chronic myeloid leukemia: Clinical and biological aspects
by: Daniele Cattaneo, et al.
Published: (2024)

The RAS‐signaling‐pathway‐mutation‐related prognosis in B‐cell acute lymphoblastic leukemia: A report from South China children's leukemia group
by: Xinyu Li, et al.
Published: (2024)

ZNF384 fusion transcript levels for measurable residual disease monitoring in adult B‐cell acute lymphoblastic leukemia
by: Zong‐Yan Shi, et al.
Published: (2024)

Treatment‐related toxicity disparities in adult Hispanic acute lymphoblastic leukemia patients receiving pegaspargase‐based regimens: A multicenter electronic health research network study
by: Benjamin J. Lee, et al.
Published: (2024)

Clonal dynamics of Richter transformation in chronic lymphocytic leukemia
by: Hanyin Wang, et al.
Published: (2024)

Real‐world data on diagnostics, treatment and outcomes of patients with hairy cell leukemia: The HCL‐CLLEAR study
by: Anna Panovská, et al.
Published: (2024)

How receptor tyrosine kinase‐like orphan receptor 1 meets its partners in chronic lymphocytic leukemia
by: Nayla Mouawad, et al.
Published: (2024)

Identifying and addressing unmet clinical needs on the use of zanubrutinib in chronic lymphocytic leukemia: A consensus‐based position paper from an ad hoc expert panel
by: Francesca Romana Mauro, et al.
Published: (2024)

Allogeneic transplantation for adult T‐cell leukemia/lymphoma in adolescent and young adults and young patients: A nationwide retrospective study by the ATL working group of the Japan society for transplantation and cellular therapy
by: Hidehiro Itonaga, et al.
Published: (2024)

CEBPA ‐bZIP Mutations in AML Patients Treated With Non‐Intensive Therapy: A Study by the Spanish PETHEMA Registry
by: Esther Prados de la Torre, et al.
Published: (2026)

416 | REAL‐LIFE DISEASE MONITORING IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA PATIENTS USING LIQUID BIOPSY ULTRA‐DEEP SEQUENCING
by: A. Jiménez Ubieto, et al.
Published: (2025)

561 | PROGNOSTIC IMPACT OF THE MUTATIONAL PROFILE IN FOLLICULAR LYMPHOMA TREATED WITH FIRST‐LINE IMMUNOCHEMOTHERAPY
by: J. Marco Ayala, et al.
Published: (2025)

Efficacy of escalating therapy with brentuximab vedotin‐AVD in advanced stage Hodgkin lymphoma patients with positive interim positron emission tomography after ABVD
by: Carmen Martínez, et al.
Published: (2024)

388 | CLINICAL OUTCOMES AND PROGNOSTIC FACTORS IN NODAL AGGRESSIVE T‐CELL LYMPHOMAS: INSIGHTS FROM 655 CASES REGISTERED IN THE T‐CELL PROJECT 2.0
by: S. Luminari, et al.
Published: (2025)

177 | GENETIC PROFILING OF MARGINAL ZONE LYMPHOMA IN ctDNA AT DIAGNOSIS AND DURING FOLLOW‐UP: DIAGNOSTIC AND PROGNOSTIC IMPLICATIONS
by: R. Diez‐Feijóo, et al.
Published: (2025)

884 | THE EMOTIONAL BURDEN OF LYMPHOMA: HOW LYMPHOMA SURVIVORS PERCEIVE RELATIONSHIPS AND SELF‐IMAGE
by: N. Shokun, et al.
Published: (2025)

566 | REAL‐WORLD OUTCOMES OF MOSUNETUZUMAB USE FROM THE CUBIC CONSORTIUM
by: A. Jallouk, et al.
Published: (2025)

263 | LONG‐TERM OUTCOMES IN WALDENSTRÖM MACROGLOBULINEMIA PATIENTS WHO DISCONTINUE BRUTON TYROSINE KINASE INHIBITOR THERAPY
by: K. L. Chohan, et al.
Published: (2025)

402 | RELAPSED/REFRACTORY PERIPHERAL T‐CELL LYMPHOMAS: REPORT ON 641 PATIENTS FROM THE T‐CELL PROJECT 2.0
by: N. Shokun, et al.
Published: (2025)

169 | PHOSPHO‐STAT3 EXPRESSION AND JAK/STAT PATHWAY ACTIVATION ACROSS GENETIC SUBTYPES OF DIFFUSE LARGE B‐CELL LYMPHOMA
by: A. A. Pomares, et al.
Published: (2025)

387 | SURVIVAL OUTCOMES FOR PATIENTS WITH EXTRA‐NODAL NK/T LYMPHOMA; DATA FROM 110 PATIENTS PROSPECTIVELY REGISTERED IN THE INTERNATIONAL T‐CELL PROJECT 2
by: C. Fox, et al.
Published: (2025)

351 | FINAL SAFETY ANALYSIS IN PARTICIPANTS WITH HEMATOLOGIC MALIGNANCIES WHO RECEIVED ALLOGENEIC STEM CELL TRANSPLANT AFTER PEMBROLIZUMAB THERAPY
by: J. Kuruvilla, et al.
Published: (2025)

692 | POST TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS: AN INTERNATIONAL REGISTRY STUDY (THE PLATO STUDY)
by: F. Cavallo, et al.
Published: (2025)

510 | THE ANTIBODY‐DEPENDENT CELLULAR CYTOTOXICITY AND METABOLIC TUMOR VOLUME BALANCE: A NOVEL PREDICTIVE MARKER FOR TUMOR RECURRENCE IN DIFFUSE LARGE B‐CELL LYMPHOMA
by: S. Rincon‐Lopez, et al.
Published: (2025)

206 | SPATIAL AND SINGLE‐CELL MULTI‐OMICS REVEAL MACROPHAGE HETEROGENEITY BETWEEN PRIMARY CNS LYMPHOMA AND DIFFUSE LARGE B‐CELL LYMPHOMA
by: L. Hong, et al.
Published: (2025)

389 | THE OUTCOME OF ADULT T‐CELL LEUKEMIA/LYMPHOMA IN REAL WORLD SETTING: INSIGHTS FROM THE T‐CELL PROJECT 2.0
by: C. S. Chiattone, et al.
Published: (2025)

853 | CTEP TRIAL 10590, NORM: NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA PATIENTS TREATED IN A RANDOMIZED PHASE II TRIAL WITH EITHER RITUXIMAB OR MOSUNETUZUMAB
by: R. Steiner, et al.
Published: (2025)

734 | REAL‐WORLD OUTCOMES OF FRONTLINE BRENTUXIMAB VEDOTIN IN OLDER PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA ‐AN INTERNATIONAL, MULTI‐CENTER STUDY
by: E. Luttwak, et al.
Published: (2025)

345 | PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA: A MULTICENTRIC OBSERVATIONAL STUDY OF SPANISH LYMPHOMA GROUP GELTAMO
by: A. Cabero Martínez, et al.
Published: (2025)

668 | REAL‐WORLD EVIDENCE OF SECOND‐LINE THERAPY IN RELAPSED/REFRACTORY LARGE B CELL LYMPHOMA: SPANISH MULTICENTER GELTAMO STUDY
by: L. Bento, et al.
Published: (2025)

Lomustine, Etoposide and Cyclophosphamide as Conditioning for Auto‐HCT in Lymphomas
by: Rafaella Cabral Samico, et al.
Published: (2025)